Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-17. (Canceled)

18. (Currently Amended) An immunogenic composition comprising

(i) antigen-presenting cells;

(ii) ~~a purified protein, the amino acid sequence of which consists essentially of an amino acid sequence of~~ a purified fragment of human Hsp 70, consisting essentially of ~~containing~~ amino acids 480-640 ~~481-641~~ of the human Hsp 70, fused to a human antigen unrelated to a heat shock protein; and

(iii) a pharmaceutically acceptable carrier,

wherein the composition is free of any human antigen that is not covalently bound to the fragment of human Hsp 70.

19. (Original) The immunogenic composition of claim 18, wherein the antigen-presenting cells include dendritic cells.

20. (Original) The immunogenic composition of claim 19, wherein the antigen-presenting cells are purified.

21. (Previously Presented) The immunogenic composition of claim 20, wherein the human antigen is alpha-fetal protein or prostate specific antigen.

22. (Original) The immunogenic composition of claim 18, wherein the antigen-presenting cells are purified.

23. (Original) The immunogenic composition of claim 18, wherein the human antigen is a tumor associated antigen.

24. (Original) The immunogenic composition of claim 18, further comprising a cytotoxic compound.

25. (Original) The immunogenic composition of claim 24, wherein the antigen-presenting cells include dendritic cells.

26. (Original) The immunogenic composition of claim 24, wherein the antigen-presenting cells are purified.

27. (Original) The immunogenic composition of claim 24, wherein the human antigen is a tumor associated antigen.

28-37. (Canceled)

38. (Previously Presented) The immunogenic composition of claim 18, wherein the human antigen is a prostate specific antigen.

39. (Previously Presented) The immunogenic composition of claim 18, wherein the human antigen is an alpha-fetal protein.

40-46. (Canceled)